评估心力衰竭患者的益处:使用新型预后风险分层的VICTORIA试验分析
Christopher M O'Connor1, Sarah Rathwell2, Devan V Mehrotra3
1Inova Schar Heart and Vascular, Falls Church, VA, USA.
Journal of cardiac failure
|August 30, 2025
概括
五步分层测试和合并常规 (5- STAR) 方法改善了心力衰竭患者的治疗疗效评估. 与标准分析相比,这种方法的治疗效益更大,突出了其在管理风险异质性的价值.
科学领域:
- 心血管医学
- 临床试验方法
- 药理学研究
背景情况:
- 随机试验是治疗评估的标准,但可能受到主要终点风险异质性的限制.
- 五步分层测试和合并常规 (5-STAR) 方法解决了这些局限性.
- 这项研究将5- STAR应用于VICTORIA试验数据库,并结合了辅助数据.
研究的目的:
- 在VICTORIA试验数据上使用5- STAR方法重新评估药剂的疗效.
- 评估风险分层对心力衰竭疗法的治疗效果估计的影响.
主要方法:
- 使用弹性网考克斯回归和条件推理树来进行风险分层,对治疗进行盲目处理.
- 核心实验室生物标志物和心电学变量被整合到数据集中.
- 对心血管死亡或心力衰竭住院 (HFH) 的综合终点进行了风险层内的比较,结果为整体推断的平均值.
主要成果:
- 与最初的VICTORIA分析 (HR: 0. 90, 95% CI: 0. 82- 0. 98) 相比,5- STAR分析显示出更高的治疗疗效 (HR: 0. 85, 95% CI: 0. 77- 0. 94).
- 对于心血管死亡 (5- STAR HR: 0. 79) 和高血压 (5- STAR HR: 0. 89) 组件均观察到增强的疗效.
- 包括GDF-15和NT-proBNP在内的5个生物标志物定义了终点上的风险层.
结论:
- 5STAR方法有效地减轻了预后风险异质性引起的治疗效应稀释.
- 这一回顾性VICTORIA分析证实了 vericiguat在初级复合终点及其组件上的更大有效性.
- 增长差异化因素15 (GDF-15) 成为综合终点及其组件中最强的预后风险因素.
更多相关视频
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
2.2K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.6K
相关概念视频
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505